{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"LLY","limit":50},"count":50,"signals":[{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"dependent compensation consultant, the Talent and Compensation Committee reviewed the companys compensation policies and practices and concluded that the programs and practices are unlikely to have a material adverse effect on the company. The Talent and Compensation Committee noted numerous policy and design features of the companys compensation programs and governance structure that reduce the likelihood of inappropri","filed_date":"2026-03-20","accession":"0000059478-26-000029","full_text":"https://origin.rootz.global/static/filing/0000059478-26-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"Shareholder Engagement on Governance Issues | 41 | | | Ownership of Company Stock | 42 | | | Compensation | 44 | | | Item 2 - Approval, on an Advisory Basis, of the Compensation Paid to the Companys Named Executive Officers | 44 | | | Talent and Compensation Committee Matters | 44 | | | Compensation Discussion and Analysis | 46 | | | Executive Compensation Tables | 59 | | | CEO Pay Ratio | 67 | | | Pay versus Performan","filed_date":"2026-03-20","accession":"0000059478-26-000029","full_text":"https://origin.rootz.global/static/filing/0000059478-26-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"s must generally opt in for coverage of anti-obesity medicines. Payers in various international markets also do not cover anti-obesity medicines for weight loss. Our anti-obesity medicines comprise a significant portion of our revenues, and barriers to reimbursable patient access impact our sales volumes, business, and results of operations. Most new products or uses that we introduce must compete with other branded, biosimilar, o","filed_date":"2026-02-12","accession":"0000059478-26-000013","full_text":"https://origin.rootz.global/static/filing/0000059478-26-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":91,"context":"ages), criminal sanctions, and administrative remedies, including exclusion from participation in government healthcare programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position in any given period. We are also subject to a variety of federal, state, local, and foreign environmental, health and safe","filed_date":"2026-02-12","accession":"0000059478-26-000013","full_text":"https://origin.rootz.global/static/filing/0000059478-26-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"pensation consultant, the Talent and Compensation Committee reviewed the companys compensation policies and practices and concluded that the programs and practices are not reasonably likely to have a material adverse effect on the company. The Talent and Compensation Committee noted numerous policy and design features of the companys compensation programs and governance structure that reduce the likelihood of inappropri","filed_date":"2025-03-21","accession":"0000059478-25-000107","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":37,"context":"Shareholder Engagement on Governance Issues | 42 | | | Ownership of Company Stock | 43 | | | Compensation | 44 | | | Item 2 - Approval, on an Advisory Basis, of the Compensation Paid to the Companys Named Executive Officers | 44 | | | Talent and Compensation Committee Matters | 45 | | | Compensation Discussion and Analysis | 46 | | | Executive Compensation Tables | 61 | | | CEO Pay Ratio | 71 | | | Pay versus Performan","filed_date":"2025-03-21","accession":"0000059478-25-000107","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"s must opt in for coverage of these medicines. Medicare and payers in various international markets also have not covered anti-obesity medicines for weight loss. Our anti-obesity medicines comprise a significant portion of our revenues, and barriers to reimbursable patient access may impact our sales volumes, business, and results of operations. Most new products or uses that we introduce must compete with other branded, biosimila","filed_date":"2025-02-19","accession":"0000059478-25-000067","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000067.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":88,"context":"ages), criminal sanctions, and administrative remedies, including exclusion from participation in government healthcare programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position in any given period. We are also subject to a variety of federal, state, local, and foreign environmental, health and safe","filed_date":"2025-02-19","accession":"0000059478-25-000067","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000067.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":50,"context":"Shareholder Engagement on Governance Issues | 44 | | | Ownership of Company Stock | 45 | | | Compensation | 46 | | | Item 2 - Approval, on an Advisory Basis, of the Compensation Paid to the Companys Named Executive Officers | 46 | | | Talent and Compensation Committee Matters | 47 | | | Compensation Discussion and Analysis | 48 | | | Executive Compensation Tables | 67 | | | CEO Pay Ratio | 76 | | | Pay versus Performan","filed_date":"2024-03-22","accession":"0000059478-24-000099","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":80,"context":"e damages), criminal sanctions, and administrative remedies, including exclusion from U.S. federal and other healthcare programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position in any given period. We are also subject to a variety of federal, state, local, and foreign environmental, health and safe","filed_date":"2024-02-21","accession":"0000059478-24-000065","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"nt with prior years), the Talent and Compensation Committee reviewed the companys compensation policies and practices and concluded that the programs and practices are not reasonably likely to have a material adverse effect on the company. The Talent and Compensation Committee noted numerous policy and design features of the companys compensation programs and governance structure that reduce the likelihood of inappropri","filed_date":"2023-03-17","accession":"0000059478-23-000120","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000120.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":62,"context":"hareholder Engagement on Governance Issues | 46 | | | Ownership of Company Stock | 49 | | | Compensation | 50 | | | | Item 2 - Approval, on an Advisory Basis, of the Compensation Paid to the Companys Named Executive Officers | 49 | | | | Talent and Compensation Committee Matters | 49 | | | | Compensation Discussion and Analysis | 51 | | | | Executive Compensation | 70 | | | | CEO Pay Ratio | 79 | | | | Pay versus Perfor","filed_date":"2023-03-17","accession":"0000059478-23-000120","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000120.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"laims Act), criminal sanctions, and administrative remedies, including exclusion from U.S. federal and other healthcare programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position in any given period. We are also subject to a variety of federal, state, local, and foreign environmental, health and safe","filed_date":"2023-02-22","accession":"0000059478-23-000082","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":53,"context":"5 | | | | Shareholder Recommendations and Nominations for Director Candidates | 35 | | | Ownership of Company Stock | 36 | | | Compensation | 37 | | | | Item 2 - Advisory Vote on Compensation Paid to Named Executive Officers | 37 | | | | Compensation Committee Matters | 38 | | | | Compensation Discussion and Analysis | 39 | | | | Executive Compensation | 55 | | | | CEO Pay Ratio | 64 | | | Audit Matters | 64 | | | | Ite","filed_date":"2022-03-18","accession":"0000059478-22-000099","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2021, 2020, and 2019. 81 As of December31, 2021, the available-for-sale secur","filed_date":"2022-02-23","accession":"0000059478-22-000068","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"aims Act), criminal sanctions, and administrative remedies, including exclusion from U.S. federal and other health care programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position. We are also subject to a variety of federal, state, local, and foreign environmental, health and safety, and other laws a","filed_date":"2022-02-23","accession":"0000059478-22-000068","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":98,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and six months ended June30, 2021 and 2020. 28 As of June30, 2021, the available-for-sale securi","filed_date":"2021-08-03","accession":"0000059478-21-000171","full_text":"https://origin.rootz.global/static/filing/0000059478-21-000171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":96,"match_count":12,"context":"pensation consultant, the Talent and Compensation Committee reviewed the companys compensation policies and practices and concluded that the programs and practices are not reasonably likely to have a material adverse effect on the company. The Talent and Compensation Committee noted numerous policy and design features of the companys compensation programs and governance structure that reduce the likelihood of inappropri","filed_date":"2024-03-22","accession":"0000059478-24-000099","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":93,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December31, 2023, 2022, and 2021.The table below summarizes the contractual maturities of","filed_date":"2024-02-21","accession":"0000059478-24-000065","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":88,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December31, 2022, 2021, and 2020. The table below summarizes the contractual maturities of","filed_date":"2023-02-22","accession":"0000059478-23-000082","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":88,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September30, 2021 and 2020. 28 As of September30, 2021, the available-for-","filed_date":"2021-10-27","accession":"0000059478-21-000216","full_text":"https://origin.rootz.global/static/filing/0000059478-21-000216.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":80,"match_count":10,"context":"ts of agreements to acquire DICE Therapeutics, Inc., Sigilon Therapeutics, Inc. and Versanis Bio. New Products(i) contributed $1.00 billion to revenue in Q2 2023, led by Mounjaro. Growth Products(ii) revenue increased 16% to $4.93 billion in Q2 2023, led by Verzenio, Jardiance and Taltz. Q2 2023 EPS increased 86% to $1.95 on a reported basis and increased 69% to $2.11 on a non-GAAP basis, both inclusive of $0.43 of EP","filed_date":"2023-08-08","accession":"0000059478-23-000219","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":78,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and six months ended June30, 2022 and 2021. 26 As of June30, 2022, the available-for-sale securi","filed_date":"2022-08-04","accession":"0000059478-22-000196","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000196.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":73,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three months ended March31, 2022 and 2021. 24 As of March31, 2022, the available-for-sale securities i","filed_date":"2022-04-29","accession":"0000059478-22-000133","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000133.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":72,"match_count":9,"context":"ncial Results and Provides 2024 Guidance Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca fo","filed_date":"2024-02-06","accession":"0000059478-24-000032","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":72,"match_count":9,"context":"Therapeutics, Inc., and the announcement of the agreement to acquire POINT Biopharma Global Inc. New Products(i) contributed $1.44 billion to revenue in Q3 2023, led by Mounjaro. Growth Products(ii) revenue increased 12% to $4.96 billion in Q3 2023, led by Verzenio and Jardiance. Q3 2023 EPS was a loss of $0.06 on a reported basis and income of $0.10 on a non-GAAP basis, both inclusive of an increase of $1.22 of EPS","filed_date":"2023-11-02","accession":"0000059478-23-000282","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000282.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":64,"match_count":8,"context":"ted by the country's evolving pharmaceutical regulatory environment, including access, intellectual property protection, regulatory enforcement and compliance, and trade policies. Governments in many emerging markets are also focused on limiting health care costs and have enacted price controls and measures impacting intellectual property. Reforms in our product markets, including those that may stem from period","filed_date":"2025-02-19","accession":"0000059478-25-000067","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000067.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":64,"match_count":8,"context":"m Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%. Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPRD charges.  2024 revenue guidance ran","filed_date":"2024-10-30","accession":"0000059478-24-000242","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000242.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":64,"match_count":8,"context":"epbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi, non-incretin revenue increased 17% worldwide and 25% in the U.S. Q2 2024 EPS increased 68% to $3.28 on a reported basis and increased 86% to $3.92 on a non-GAAP basis, both inclusive of $0.14 of acquired IPRD charges. 2024 full-year r","filed_date":"2024-08-08","accession":"0000059478-24-000185","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":64,"match_count":8,"context":"e impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; regulatory changes or other developments; regulatory actions regarding operations and products;  continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; devaluations in foreign currency exchange rates or changes in int","filed_date":"2023-02-22","accession":"0000059478-23-000082","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":64,"match_count":8,"context":"l Results Reflect Lilly's Continued Momentum into 2022  Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%. Outside of revenue from COVID-19 antibodies, which grew $660 million, revenue was driven by key growth products - consisting of Trulicity, Verzenio, Jardiance, Taltz, Olumiant, Emgality, Retevmo, Cy","filed_date":"2022-04-28","accession":"0000059478-22-000130","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":63,"match_count":1,"context":"s and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September30, 2022 and 2021. 27 As of September30, 2022, the available-for-","filed_date":"2022-11-01","accession":"0000059478-22-000250","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":56,"match_count":7,"context":"es were primarily driven by Mounjaro, partially offset by Zepbound and Humalog. New Products1 revenue grew by $3.15 billion to $5.64 billion in Q4 2024, led by Zepbound and Mounjaro. Growth Products2 revenue increased 13% to $5.95 billion in Q4 2024 driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. The growth in Jardiance revenue included a one-time benefit of $300.0 million associ","filed_date":"2025-02-06","accession":"0000059478-25-000037","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":56,"match_count":7,"context":"by the country's evolving pharmaceutical regulatory environment, including access, intellectual property protection, regulatory enforcement and compliance, and trade policies. 17 Governments in many emerging markets are also focused on limiting health care costs and have enacted price controls and measures impacting intellectual property. Reforms in our product markets, including those that may stem from period","filed_date":"2024-02-21","accession":"0000059478-24-000065","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":56,"match_count":7,"context":"4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than offset volume growth from key growth products. Total revenue grew 6% excluding revenue from Alimta, the sale of the company's rights to Cialis in China in Q2 2021, and COVID-19 antibodies. The company continued to advance its pipeline with the U.S. approval and launch","filed_date":"2022-08-04","accession":"0000059478-22-000194","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"posed  5 nominee (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a voting commitment) that has not been disclosed to the Corporation or (B) any voting commitment that could limit or interfere with such","filed_date":"2022-05-04","accession":"0000059478-22-000138","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"proposed nominee (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a voting commitment) that has not been disclosed to the Corporation or (B) any voting commitment that could limit or interfere with such","filed_date":"2021-12-16","accession":"0001193125-21-359144","full_text":"https://origin.rootz.global/static/filing/0001193125-21-359144.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":56,"match_count":7,"context":"g to our facilities; reliance on third-party relationships and outsourcing arrangements; regulatory changes or other developments; regulatory actions regarding currently marketed products;  continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; devaluations in foreign currency exchange rates or changes in int","filed_date":"2021-08-03","accession":"0000059478-21-000171","full_text":"https://origin.rootz.global/static/filing/0000059478-21-000171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":55,"match_count":5,"context":"d, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.Litigation accruals and environmental liabil","filed_date":"2025-10-30","accession":"0000059478-25-000254","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000254.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":55,"match_count":5,"context":"d, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.Litigation accruals and environmental liabil","filed_date":"2025-08-07","accession":"0000059478-25-000204","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000204.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":55,"match_count":5,"context":"d, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.Litigation accruals and environmental liabil","filed_date":"2025-05-01","accession":"0000059478-25-000132","full_text":"https://origin.rootz.global/static/filing/0000059478-25-000132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":55,"match_count":5,"context":"d, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.Litigation accruals and environmental liabil","filed_date":"2026-04-30","accession":"0000059478-26-000045","full_text":"https://origin.rootz.global/static/filing/0000059478-26-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":55,"match_count":5,"context":"d, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.Litigation accruals and environmental liabil","filed_date":"2026-08-05","accession":"0000059478-26-000081","full_text":"https://origin.rootz.global/static/filing/0000059478-26-000081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":48,"match_count":6,"context":"stimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.Litigation accruals and environmental liabil","filed_date":"2024-10-30","accession":"0000059478-24-000245","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000245.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":48,"match_count":6,"context":"ons to base periods, as the $25 non-covered benefit expired June 30, 2023. New Products(i) revenue grew by $1.79 billion to $2.39 billion in Q1 2024, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 2% to $4.66 billion in  | | | | | | (i) Lilly defines New Products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Mounjaro, Omvoh and Zepbound.(ii) Lilly defines G","filed_date":"2024-04-30","accession":"0000059478-24-000116","full_text":"https://origin.rootz.global/static/filing/0000059478-24-000116.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":48,"match_count":6,"context":"ubmissions of tirzepatide for obesity in the EU and lebrikizumab for atopic dermatitis in Japan. New Products(i) contributed $573.6 million to revenue in Q1 2023, led by Mounjaro. Growth Products(ii) revenue increased 18% to $4.56 billion in Q1 2023, led by Verzenio, Trulicity, Jardiance and Taltz. Driven by the decline in COVID-19 antibodies revenue, Q1 2023 EPS decreased 29% to $1.49 on a reported basis and decrease","filed_date":"2023-04-27","accession":"0000059478-23-000160","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":48,"match_count":6,"context":"regulatory authorizationsNM not meaningful | | | | | | | | | 8 | | | | | | | | | | Trulicity For Q4 2022, worldwide Trulicity revenue was $1.94 billion, an increase of 3% compared with Q4 2021. U.S. revenue increased 5% to $1.53 billion, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. was $409.8 million, a decrease of 6%, driven by the unfavorable impact of foreign exc","filed_date":"2023-02-02","accession":"0000059478-23-000025","full_text":"https://origin.rootz.global/static/filing/0000059478-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":48,"match_count":6,"context":"Q3 2022, excluding revenue from COVID-19 antibodies. Excluding revenue from Alimta, which lost exclusivity in major markets, COVID-19 antibodies, and Olumiant for the treatment of COVID-19, worldwide revenue increased 9% in Q3 2022. Revenue in the U.S. increased 11% to $4.42 billion, driven by a 15% increase in volume, partially offset by a 4% decrease due to lower realized prices. Excluding revenue from Alimta, COVI","filed_date":"2022-11-01","accession":"0000059478-22-000248","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000248.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"etainers and meeting fees in effect in 2021 for all non-employee directors | | | | | | | | | | | | | | | | | | | | | | | | | | | Board and Committee Membership Retainers (annual, paid in monthly installments) | | | Leadership Retainers (annual, paid in monthly installments) | | | | | | | | | Annual board retainer | $110,000 | | Lead independent director | $35,000 | | | | | | | | | Audit Committee and","filed_date":"2022-03-18","accession":"0000059478-22-000099","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LLY","company":"ELI LILLY & Co","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":48,"match_count":6,"context":"1 (consistent with prior years), the Compensation Committee reviewed the companys compensation policies and practices and concluded that the programs and practices are not reasonably likely to have a material adverse effect on the company. The Compensation Committee noted numerous policy and design features of the companys compensation programs and governance structure that reduce the likelihood of inappropriate risk-ta","filed_date":"2022-03-18","accession":"0000059478-22-000099","full_text":"https://origin.rootz.global/static/filing/0000059478-22-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"0bcbe00264562ccc8e961b061ae8ad6cdfd15f212a78498228cbe315955f483d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7f509a8764949991f6aa272b531de44b10ca3cf7abba77dc502f086ce1a2f77f","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":19,"hourly_limit":500,"remaining":481,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}